RWA
ZNTL icon

Ropes Wealth Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ropes Wealth Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10
Closed -$1K – 822
2020
Q4 		$1K Buy
+10
New +$451 ﹤0.01% 794

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Ropes Wealth Advisors's ZNTL Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2021, closing a stake of 10 shares — an estimated $1K sold.

Ropes Wealth Advisors first reported a position in ZNTL in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 95 funds tracked by Wall St. Rank hold ZNTL as of Q1 2021.

  • Ropes Wealth Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Ropes Wealth Advisors sold 10 Zentalis Pharmaceuticals shares in Q1 2021, an estimated $1K.
  • Ropes Wealth Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Ropes Wealth Advisors's Zentalis Pharmaceuticals position peaked at $1K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.